Investment Ratings - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine sectors, while the biopharmaceutical sector is rated as Neutral [1][6]. Core Insights - The pharmaceutical sector experienced a decline of 1.92% on September 2, 2024, underperforming the CSI 300 index by 0.22 percentage points, ranking 19th among 31 sub-industries in the Shenwan classification [4]. - Among the sub-industries, blood products (-1.33%), pharmaceutical distribution (-1.53%), and medical consumables (-1.60%) performed relatively well, while offline pharmacies (-7.27%), hospitals (-3.70%), and medical research outsourcing (-3.38%) lagged behind [4]. - Notable individual stock performances included Guanhao Biological (+20.02%), Nanhua Biological (+10.07%), and Zhongyuan Xiehe (+10.00%) on the gainers' list, while Lixin Medical (-13.98%), Chunli Medical (-10.15%), and Laobaixing (-9.33%) were among the biggest losers [4]. Industry Summary - Accuredit announced that its self-developed in vivo gene editing drug ART001 received clinical trial approval from the FDA, aimed at treating transthyretin amyloidosis (ATTR) [5]. - Zhongsheng Pharmaceutical's subsidiary received acceptance for a clinical trial application for a new indication of the innovative polypeptide drug RAY1225 [5]. - Yuandong Bio's subsidiary received a drug registration certificate for a new oral solution [5]. - Sailong Pharmaceutical's subsidiary obtained approval for omeprazole sodium [5]. - Chengda Bio's subsidiary received acceptance for a rabies vaccine registration application [5].
医药行业周报：Accuredit在研基因编辑疗法获FDA临床批准
Tai Ping Yang·2024-09-04 01:02